MX2020002762A - Composiciones y métodos para tratar una lesión cerebral. - Google Patents

Composiciones y métodos para tratar una lesión cerebral.

Info

Publication number
MX2020002762A
MX2020002762A MX2020002762A MX2020002762A MX2020002762A MX 2020002762 A MX2020002762 A MX 2020002762A MX 2020002762 A MX2020002762 A MX 2020002762A MX 2020002762 A MX2020002762 A MX 2020002762A MX 2020002762 A MX2020002762 A MX 2020002762A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating
brain injury
compounds
Prior art date
Application number
MX2020002762A
Other languages
English (en)
Inventor
Michael J Brownstein
Original Assignee
Azevan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azevan Pharmaceuticals Inc filed Critical Azevan Pharmaceuticals Inc
Publication of MX2020002762A publication Critical patent/MX2020002762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Compuestos y composiciones, métodos y usos de estos, se describen en la presente para tratar lesiones cerebrales.
MX2020002762A 2017-09-15 2018-09-17 Composiciones y métodos para tratar una lesión cerebral. MX2020002762A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762559113P 2017-09-15 2017-09-15
US201762584343P 2017-11-10 2017-11-10
US201862658758P 2018-04-17 2018-04-17
PCT/US2018/051331 WO2019055913A1 (en) 2017-09-15 2018-09-17 COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY

Publications (1)

Publication Number Publication Date
MX2020002762A true MX2020002762A (es) 2020-09-17

Family

ID=65723435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002762A MX2020002762A (es) 2017-09-15 2018-09-17 Composiciones y métodos para tratar una lesión cerebral.

Country Status (14)

Country Link
US (2) US11628160B2 (es)
EP (1) EP3681871A4 (es)
JP (2) JP2020534274A (es)
KR (1) KR102790657B1 (es)
CN (1) CN111295373B (es)
AU (1) AU2018333051B2 (es)
BR (1) BR112020005107A2 (es)
CA (1) CA3075759A1 (es)
IL (1) IL273228B2 (es)
MX (1) MX2020002762A (es)
MY (1) MY208313A (es)
TW (1) TW201919625A (es)
WO (1) WO2019055913A1 (es)
ZA (1) ZA202001880B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2662350T3 (es) 2010-07-01 2018-04-06 Azevan Pharmaceuticals, Inc. Procedimientos para el tratamiento del trastorno por estrés postraumático
AU2015237253B2 (en) 2014-03-28 2019-11-14 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
MX2018011765A (es) * 2016-03-30 2019-05-20 Sinntaxis AB Moduladores alostéricos negativos del receptor 5 metabotrópico de glutamato (mglur5) para su uso en el tratamiento de daños cerebrales maduros.
MY208313A (en) 2017-09-15 2025-04-30 Azevan Pharmaceuticals Inc Compositions and methods for treating brain injury
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
CN115350186A (zh) * 2022-08-31 2022-11-18 中国人民解放军军事科学院军事医学研究院 Sxr246在制备治疗创伤性脑损伤及预后不良药物中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4341698A (en) 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS6033439B2 (ja) 1980-03-07 1985-08-02 財団法人相模中央化学研究所 ジペプチドの製造方法
JPS56125361A (en) 1980-03-07 1981-10-01 Sagami Chem Res Center Azetidinone compound
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
CA2093125C (en) 1990-10-02 2003-12-16 Warner-Lambert Company Angiotensin ii antagonists
GB9204001D0 (en) 1992-02-25 1992-04-08 Jacobs Suchard Ag Process for producing reduced fat nuts
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
AU4713293A (en) 1992-07-13 1994-01-31 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
EP1000930A3 (en) 1992-08-13 2003-10-29 Warner-Lambert Company Tachykinin antagonists
FR2696178B1 (fr) 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
HU224496B1 (hu) 1993-05-06 2005-10-28 Merrel Dow Pharmaceuticals Inc. Pirrolidin-3-il-alkil-piperidin-származékok és e vegyületeket tartalmazó gyógyászati készítmények
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5759865A (en) 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
DE69734321T2 (de) 1996-02-23 2006-08-10 Eli Lilly And Co., Indianapolis Non-peptidische vasopressin via antagonisten
BR9714394A (pt) 1996-12-13 2000-05-16 Lilly Co Eli Inibidores da atividade enzimática de psa
EP0987266A4 (en) * 1997-03-31 2000-07-26 Wakamoto Pharma Co Ltd BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS
CN1183134C (zh) 1997-07-30 2005-01-05 惠氏公司 三环后叶加压素激动剂
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
AU749505B2 (en) 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6610681B1 (en) 1999-08-16 2003-08-26 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
NZ532033A (en) 2001-10-12 2006-11-30 Azevan Pharmaceuticals Inc 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives as vasopressin V1a receptor antagonists
AU2002359761A1 (en) 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
TWI335328B (en) 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
TW200526651A (en) 2003-10-03 2005-08-16 Serenix Pharmaceuticals Llc 3-substituted β-lactamyl vasopressin V1a antagonists
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP1669776A1 (de) 2004-12-11 2006-06-14 Leica Geosystems AG Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
US20080234252A1 (en) 2005-05-18 2008-09-25 Pfizer Inc Compounds Useful in Therapy
TR201907381T4 (tr) 2005-07-19 2019-06-21 Azevan Pharmaceuticals Inc Beta-laktamil fenilalanin, sistein ve serin vazopressin antagonisti.
WO2007109615A2 (en) 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
US20100016274A1 (en) 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
PL2078022T3 (pl) 2006-09-22 2012-04-30 Janssen Pharmaceutica Nv Spirobenzoazepiny stosowane jako antagoniści wazopresyny
AU2007299822A1 (en) 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
CA2681695A1 (en) 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
ES2662350T3 (es) * 2010-07-01 2018-04-06 Azevan Pharmaceuticals, Inc. Procedimientos para el tratamiento del trastorno por estrés postraumático
CN102156420B (zh) 2010-12-23 2012-11-07 天津职业技术师范大学 加快从计算机下载数据到单片机目标存储器的装置
EP2956441A4 (en) * 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
AU2015237253B2 (en) * 2014-03-28 2019-11-14 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
MY208313A (en) * 2017-09-15 2025-04-30 Azevan Pharmaceuticals Inc Compositions and methods for treating brain injury

Also Published As

Publication number Publication date
US11628160B2 (en) 2023-04-18
TW201919625A (zh) 2019-06-01
EP3681871A1 (en) 2020-07-22
BR112020005107A2 (pt) 2020-11-03
CN111295373A (zh) 2020-06-16
KR102790657B1 (ko) 2025-04-02
US20200276167A1 (en) 2020-09-03
IL273228B1 (en) 2024-12-01
JP2023179559A (ja) 2023-12-19
EP3681871A4 (en) 2021-05-26
CA3075759A1 (en) 2019-03-21
AU2018333051B2 (en) 2024-03-21
AU2018333051A1 (en) 2020-03-26
CN111295373B (zh) 2024-12-10
RU2020110038A3 (es) 2021-10-15
IL273228A (en) 2020-04-30
ZA202001880B (en) 2022-06-29
IL273228B2 (en) 2025-04-01
KR20200071075A (ko) 2020-06-18
JP2020534274A (ja) 2020-11-26
US20240115553A1 (en) 2024-04-11
MY208313A (en) 2025-04-30
WO2019055913A1 (en) 2019-03-21
RU2020110038A (ru) 2021-10-15
JP7699634B2 (ja) 2025-06-27

Similar Documents

Publication Publication Date Title
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
CO2019007829A2 (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
MX386598B (es) Compuestos antibacterianos.
LT3513809T (lt) Medicininė kompozicija, apimanti tivozanibą
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
BR112016025997A2 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
MX373703B (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
GB2541571A (en) Pharmaceutical compositions
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MY208313A (en) Compositions and methods for treating brain injury
IL271728A (en) Materials, uses and treatment methods
CO2018007237A2 (es) Reguladores del cftr y métodos para su uso
MX392383B (es) Metodos para tratar afecciones oculares.
IL270070B1 (en) Compounds, compositions and methods of treating or preventing acute lung injury
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
BR112018009745A2 (pt) compostos heterocíclicos para o tratamento de doença
IT201700104446A1 (it) Compositions, uses and methods for treatment of infertility and subfertility
EP3615020A4 (en) METHODS, AGENTS AND COMPOSITIONS FOR TREATMENT OF ACUTE MYELOIC LEUKEMIA
PL3423440T3 (pl) Pochodna 5-metylo-6-fenylo-4,5-dihydro-2h-pirydazyn-3-onu do leczenia nowotworów mózgu
MX2018004632A (es) Metodos y composiciones para el tratamiento de una lesion cerebral traumatica.
IL269769B (en) Compounds, composition and uses thereof for treating cancer